RGNCY-0035 (ALK Inhibitor)
RGNCY-0035 is a potent inhibitor across a broad panel of engineered ALK mutant cell lines and showed suitable preclinical pharmacokinetics and robust tumor growth inhibition in a crizotinib-resistant cell line (H3122-L1196M). A promising clinical candidate for treating crizotinib-sensitive and resistant ALK-positive NSCLC patients.
Systematic Name: 2-(5-(6-amino-5-((R)-1-(5-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)ethoxy)pyridin-3-yl)-4-methylthiazol-2-yl)propane-1,2-diol
Mol. Wt.: 470.52
Reference: Lu, Xiaoyun, and Ke Ding. "Novel Anaplastic Lymphoma Kinase Inhibitors Targeting Clinically Acquired Resistance." Journal of Medicinal Chemistry 57.4 (2014): 1167-1169.
Interested in this reagent? E-mail us at firstname.lastname@example.org and let us know.
Tags: Cancer, ALK, Tumor, RGNCY-0035, H3122, NSCLC